Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk Meeting Abstract
| Authors: | Shah, R.; Botteman, M.; Kwon, Y.; Gooden, K. M.; Cella, D.; Motzer, R. |
| Abstract Title: | Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk |
| Meeting Title: | ISPOR 2019 |
| Journal Title: | Value in Health |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 May 18-22 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 1098-3015 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2019-05-01 |
| Start Page: | S106 |
| Language: | English |
| ACCESSION: | WOS:000472670100337 |
| DOI: | 10.1016/j.jval.2019.04.385 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PCN264 -- Source: Wos |
